Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
DH6GK7
|
|||
Drug Name |
ADG116
|
|||
Drug Type |
Antibody
|
|||
Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [1] | |
Company |
Adagene
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Cytotoxic T-lymphocyte protein 4 (CTLA-4) | Target Info | Inhibitor | [2] |
KEGG Pathway | Cell adhesion molecules (CAMs) | |||
T cell receptor signaling pathway | ||||
Autoimmune thyroid disease | ||||
Rheumatoid arthritis | ||||
Pathway Interaction Database | Calcineurin-regulated NFAT-dependent transcription in lymphocytes | |||
Reactome | CTLA4 inhibitory signaling | |||
WikiPathways | Vitamin D Receptor Pathway | |||
T-Cell Receptor and Co-stimulatory Signaling | ||||
Allograft Rejection | ||||
Costimulation by the CD28 family |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT04501276) ADG116 in Patients With Advanced/Metastatic Solid Tumors. U.S. National Institutes of Health. | |||
REF 2 | Clinical pipeline report, company report or official report of Adagene. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.